165 related articles for article (PubMed ID: 38702426)
1. Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy.
Miyamoto A; Michimae H; Nakahara Y; Akagawa S; Nakagawa K; Minegishi Y; Ogura T; Hontsu S; Date H; Takahashi K; Homma S; Kishi K;
Sci Rep; 2024 May; 14(1):10162. PubMed ID: 38702426
[TBL] [Abstract][Full Text] [Related]
2. The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias.
Minegishi Y; Kuribayashi H; Kitamura K; Mizutani H; Kosaihira S; Okano T; Seike M; Azuma A; Yoshimura A; Kudoh S; Gemma A
J Thorac Oncol; 2011 Apr; 6(4):801-7. PubMed ID: 21336181
[TBL] [Abstract][Full Text] [Related]
3. Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.
Fukuizumi A; Minegishi Y; Omori M; Atsumi K; Takano N; Hisakane K; Takahashi S; Kobayashi K; Sugano T; Takeuchi S; Noro R; Seike M; Kubota K; Azuma A; Gemma A
Int J Clin Oncol; 2019 Dec; 24(12):1543-1548. PubMed ID: 31352631
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy versus best supportive care in advanced lung cancer and idiopathic interstitial pneumonias: A retrospective multi-centre cohort study.
Miyamoto A; Michimae H; Nakahara Y; Akagawa S; Nakagawa K; Minegishi Y; Ogura T; Hontsu S; Date H; Takahashi K; Homma S; Kishi K;
Respir Investig; 2023 Mar; 61(2):284-295. PubMed ID: 36496345
[TBL] [Abstract][Full Text] [Related]
5. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation.
Koyama N; Iwai Y; Nagai Y; Aoshiba K; Nakamura H
PLoS One; 2019; 14(8):e0221718. PubMed ID: 31442290
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
Shirasawa M; Fukui T; Kusuhara S; Hiyoshi Y; Nakahara Y; Nishinarita N; Igawa S; Naoki K
BMC Cancer; 2019 Feb; 19(1):163. PubMed ID: 30808322
[TBL] [Abstract][Full Text] [Related]
9. Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study.
Kato M; Yamada T; Kataoka S; Arai Y; Miura K; Ochi Y; Ihara H; Koyama R; Sasaki S; Takahashi K
Respir Res; 2019 Dec; 20(1):287. PubMed ID: 31852459
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.
Nakao S; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Anticancer Res; 2019 Oct; 39(10):5725-5731. PubMed ID: 31570474
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study.
Omori M; Minegishi Y; Uruga H; Fukuizumi A; Isobe K; Izumi S; Koyama R; Bando M; Sugiyama H; Takahashi K; Gemma A; Homma S; Sugiyama Y; Kishi K
Respir Investig; 2023 Sep; 61(5):625-631. PubMed ID: 37441903
[TBL] [Abstract][Full Text] [Related]
12. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy.
Minegishi Y; Takenaka K; Mizutani H; Sudoh J; Noro R; Okano T; Azuma A; Yoshimura A; Ando M; Tsuboi E; Kudoh S; Gemma A
Intern Med; 2009; 48(9):665-72. PubMed ID: 19420811
[TBL] [Abstract][Full Text] [Related]
13. Difference in benefit of chemotherapy between small cell lung cancer patients with interstitial pneumonia and patients with non-small cell lung cancer.
Kashiwabara K; Semba H; Fujii S; Tsumura S; Aoki R
Anticancer Res; 2015 Feb; 35(2):1065-71. PubMed ID: 25667495
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
15. Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema.
Minegishi Y; Kokuho N; Miura Y; Matsumoto M; Miyanaga A; Noro R; Saito Y; Seike M; Kubota K; Azuma A; Kida K; Gemma A
Lung Cancer; 2014 Aug; 85(2):258-63. PubMed ID: 24894326
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease.
Kato M; Shukuya T; Takahashi F; Mori K; Suina K; Asao T; Kanemaru R; Honma Y; Muraki K; Sugano K; Shibayama R; Koyama R; Shimada N; Takahashi K
BMC Cancer; 2014 Jul; 14():508. PubMed ID: 25012241
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.
Choi MK; Hong JY; Chang W; Kim M; Kim S; Jung HA; Lee SJ; Park S; Chung MP; Sun JM; Park K; Ahn MJ; Ahn JS
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1217-25. PubMed ID: 24696125
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
